Related references
Note: Only part of the references are listed.Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium
Bastian Neesgaard et al.
LANCET HIV (2022)
Combating Inflammation in Cardiovascular Disease
Anver M. Sethwala et al.
HEART LUNG AND CIRCULATION (2021)
Role of interleukin-15 in cardiovascular diseases
Guo Lei et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Revisiting the PD-1 pathway
Nikolaos Patsoukis et al.
SCIENCE ADVANCES (2020)
Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
Steven K. Grinspoon et al.
AMERICAN HEART JOURNAL (2019)
Single-cell immune landscape of human atherosclerotic plaques
Dawn M. Fernandez et al.
NATURE MEDICINE (2019)
High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD) A Randomized Superiority Trial
Isao Taguchi et al.
CIRCULATION (2018)
Benefits and Risks of Statin Therapy in the HIV-Infected Population
Mosepele Mosepele et al.
CURRENT INFECTIOUS DISEASE REPORTS (2018)
Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study
Lene Ryom et al.
LANCET HIV (2018)
Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling
Isobel Okoye et al.
ONCOTARGET (2017)
Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial
Judith A. Aberg et al.
LANCET HIV (2017)
Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV
Mabel Toribio et al.
AIDS (2017)
Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013
Matthew J. Feinstein et al.
AMERICAN JOURNAL OF CARDIOLOGY (2016)
Statins to improve cardiovascular outcomes in treated HIV infection
Chris T. Longenecker et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2016)
Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study
Asita Wongprikorn et al.
PLOS ONE (2016)
Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21
Eleni M. Domouzoglou et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2015)
Markers of Inflammation Associated with Plaque Progression and Instability in Patients with Carotid Atherosclerosis
Enrico Ammirati et al.
MEDIATORS OF INFLAMMATION (2015)
The Role of Statins in the Setting of HIV Infection
Allison Ross Eckard et al.
CURRENT HIV/AIDS REPORTS (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events
Antonella d'Arminio Monforte et al.
AIDS (2013)
HIV-associated chronic immune activation
Mirko Paiardini et al.
IMMUNOLOGICAL REVIEWS (2013)
Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models
E. Ammirati et al.
Journal of the American Heart Association (2013)
High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial
Anuradha Ganesan et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen
Jade Ghosn et al.
ANTIVIRAL THERAPY (2010)
Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study
Signe Westring Worm et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Cheryl L. Day et al.
NATURE (2006)
Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization
H Fujino et al.
XENOBIOTICA (2003)
Share Paper
